- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
- Arbutus to Participate in Jefferies Global Healthcare Conference
- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
More ▼
Key statistics
On Tuesday, Arbutus Biopharma Corp (0SGC:LSE) closed at 3.84, -0.64% below its 52-week high of 3.86, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 3.84 |
Low | 3.84 |
Bid | -- |
Offer | -- |
Previous close | 3.84 |
Average volume | 1.69k |
---|---|
Shares outstanding | 188.72m |
Free float | 146.66m |
P/E (TTM) | -- |
Market cap | 719.01m USD |
EPS (TTM) | -0.4393 USD |
Data delayed at least 20 minutes, as of Jul 23 2024 15:54 BST.
More ▼